發(fā)布時間：2019-01-10 14:21

【摘要】：目的:對某院干部門診口服降糖藥的應用情況進行分析,提供臨床合理用藥的參考。方法:隨機抽取2012—2014年某院干部門診2型糖尿病患者處方2 108份,采用限定日劑量(DDD)法,對其使用的口服降糖藥的藥品種類、限定日費用(DDC)、用藥頻度(DDDs)、藥物利用指數(shù)(DUI)、銷售金額及其聯(lián)合用藥情況進行統(tǒng)計分析。結果:該院干部門診口服降糖藥銷售金額逐年上升,阿卡波糖銷售金額連續(xù)3年排在首位,二甲雙胍、阿卡波糖、瑞格列奈DDDs值連續(xù)3年名列前三,除格列吡嗪(緩釋)、瑞格列奈、羅格列酮外其余藥物DUI值≤1。結論:該院干部門診口服降糖藥應用基本合理。
[Abstract]:Objective: to analyze the application of oral hypoglycemic drugs in a cadre outpatient clinic. Methods: a total of 2 108 prescriptions of type 2 diabetes mellitus patients were randomly selected from a cadre outpatient clinic in a certain hospital from 2012 to 2014. The drug types of oral hypoglycemic drugs used by them were determined by the method of limited daily dose (DDD), and the frequency of (DDC), drug use was limited by daily cost (DDDs),. Drug utilization index (DUI),) sales sum and its combined drug use were statistically analyzed. Results: the sales amount of oral hypoglycemic drugs increased year by year. The sales amount of acarbose was ranked first for 3 consecutive years. The DDDs value of metformin, acarbose and Regellinide ranked first for 3 consecutive years, except for glipizide (sustained release). The DUI of repaglinide and rosiglitazone were 鈮，

本文編號：2406414